This study explored patients' and healthcare professionals' views and knowledge of pharmacogenetic testing and associated future service development. Patients and healthcare professionals discussed ...
The treatment of clinical depression presents unique challenges, with many patients voicing concerns that echo a disheartening struggle: "I have tried every medication for depression, and nothing ...
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage ...
Most antidepressants are metabolized through the cytochrome P (CYP) 450 pathway; therefore, most drug metabolism genes on pharmacogenetic testing panels are related to CYP450 oxidase enzyme subunits.
Have you ever wondered why certain medications don’t seem to work as well for you as they do for others? This variability in drug response is what pharmacogenomic testing hopes to explain by looking ...
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, a leader in medication management and personalized medicine through pharmacogenetics (PGx), is proud to announce the release of its innovative Patient ...
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need ...
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a ...
Genedrive (GB:GDR) has released an update. Genedrive PLC, a leader in pharmacogenetic testing, continues to innovate with its Genedrive® MT-RNR1 ID Kit and CYP2C19 ID Kit, enhancing personalized ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback